YMAB Y-MABS THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2025, Y-MABS THERAPEUTICS INC reported revenue of $19.5M (down 14.4% from a year earlier), net income of −$3.24M and diluted EPS of −$0.07; over the last four quarters revenue was $85.4M and net income −$22.2M; for the fiscal year ended December 2024 revenue was $87.7M, up 3.4% on the year before.

YMAB annual revenue and earnings

• Fiscal year ended Dec 2024: revenue $87.7M, gross profit $72.7M, operating income −$31.2M, net income −$29.7M (margin -33.8%), EPS −$0.67
• Fiscal year ended Dec 2023: revenue $84.8M, gross profit $73.5M, operating income −$25.7M, net income −$21.4M (margin -25.3%), EPS −$0.49
• Fiscal year ended Dec 2022: revenue $65.3M, gross profit n/a, operating income −$94.8M, net income −$95.6M (margin -146.4%), EPS −$2.19
• Fiscal year ended Dec 2021: revenue $34.9M, gross profit n/a, operating income −$115M, net income −$55.3M (margin -158.4%), EPS −$1.28

YMAB quarterly revenue and earnings

• Quarter ended Jun 30, 2025: revenue $19.5M (down 14.4% year over year), net income −$3.24M, EPS −$0.07
• Quarter ended Mar 31, 2025: revenue $20.9M (up 4.9% year over year), net income −$5.20M, EPS −$0.12
• Quarter ended Dec 31, 2024 (from the annual report): revenue $26.5M (up 13.4% year over year), net income −$6.79M, EPS −$0.15
• Quarter ended Sep 30, 2024: revenue $18.5M (down 9.7% year over year), net income −$7.00M, EPS −$0.16
• Quarter ended Jun 30, 2024: revenue $22.8M (up 9.9% year over year), net income −$9.25M, EPS −$0.21
• Quarter ended Mar 31, 2024: revenue $19.9M (down 1.6% year over year), net income −$6.63M, EPS −$0.15
• Quarter ended Dec 31, 2023 (from the annual report): revenue $23.4M (down 25.7% year over year), net income −$988K, EPS −$0.02
• Quarter ended Sep 30, 2023: revenue $20.5M (up 63.1% year over year), net income −$7.75M, EPS −$0.18
• Quarter ended Jun 30, 2023: revenue $20.8M (up 92.2% year over year), net income −$6.30M, EPS −$0.14
• Quarter ended Mar 31, 2023: revenue $20.3M (up 93.1% year over year), net income −$6.39M, EPS −$0.15
• Quarter ended Dec 31, 2022 (from the annual report): revenue $31.4M (up 227.6% year over year), net income $1.16M, EPS $0.02
• Quarter ended Sep 30, 2022: revenue $12.5M (up 39.8% year over year), net income −$27.5M, EPS −$0.63
• Quarter ended Jun 30, 2022: revenue $10.8M (down 1.4% year over year), net income −$41.1M, EPS −$0.94
• Quarter ended Mar 31, 2022: revenue $10.5M (up 94.8% year over year), net income −$28.1M, EPS −$0.64
• Quarter ended Dec 31, 2021 (from the annual report): revenue $9.60M, net income −$36.9M, EPS −$0.84
• Quarter ended Sep 30, 2021: revenue $8.97M, net income −$28.9M, EPS −$0.66
• Quarter ended Jun 30, 2021: revenue $11.0M, net income −$22.9M, EPS −$0.53
• Quarter ended Mar 31, 2021: revenue $5.38M, net income $33.4M, EPS $0.75

YMAB cash flow, buybacks and dividends

• Fiscal year ended Dec 2024: operating cash flow −$15.7M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$27.2M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$75.9M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$103M, share buybacks n/a

YMAB balance sheet

• Jun 30, 2025: cash $62.3M, total assets $117M, total liabilities $29.7M, shareholders' equity $87.5M
• Mar 31, 2025: cash $60.3M, total assets $113M, total liabilities $23.2M, shareholders' equity $89.5M
• Dec 31, 2024: cash $67.2M, total assets $120M, total liabilities $27.9M, shareholders' equity $92.0M
• Sep 30, 2024: cash $68.1M, total assets $121M, total liabilities $28.5M, shareholders' equity $92.4M
• Jun 30, 2024: cash $77.8M, total assets $144M, total liabilities $48.7M, shareholders' equity $95.3M
• Mar 31, 2024: cash $75.7M, total assets $123M, total liabilities $24.1M, shareholders' equity $99.2M
• Dec 31, 2023: cash $78.6M, total assets $128M, total liabilities $26.9M, shareholders' equity $101M
• Sep 30, 2023: cash $86.6M, total assets $129M, total liabilities $28.7M, shareholders' equity $100M

What is YMAB's revenue?

Y-MABS THERAPEUTICS INC reported $85.4M of revenue over its last four quarters, through June 30, 2025.

Is YMAB profitable?

No. Y-MABS THERAPEUTICS INC lost $22.2M over the last four quarters.

What is YMAB's EPS?

Diluted earnings per share over the last four quarters were −$0.50; −$0.07 in the latest quarter.

YMAB ownership and insider trades · All stocks